Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

BACKGROUND: We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with an encouraging rate of pathologic response. Building on these results, and promising data for nivolumab plus ipilimumab (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Reuss, Joshua E, Anagnostou, Valsamo, Cottrell, Tricia R, Smith, Kellie N, Verde, Franco, Zahurak, Marianna, Lanis, Mara, Murray, Joseph C, Chan, Hok Yee, McCarthy, Caroline, Wang, Daphne, White, James R, Yang, Stephen, Battafarano, Richard, Broderick, Stephen, Bush, Errol, Brock, Malcolm, Ha, Jinny, Jones, David, Merghoub, Taha, Taube, Janis, Velculescu, Victor E, Rosner, Gary, Illei, Peter, Pardoll, Drew M, Topalian, Suzanne, Naidoo, Jarushka, Levy, Ben, Hellmann, Matthew D, Brahmer, Julie R, Chaft, Jamie E, Forde, Patrick M
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Short Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7488786/
https://ncbi.nlm.nih.gov/pubmed/32929052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001282
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados